IL6 and polymyalgia rheumatica: This is an anti-IL6 monoclonal antibody and a phase 3 clinical candidate for rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis and also phase 2 clinical candidate for major depressive disorder [28,29].